Interpace Biosciences, Inc. (IDXG)
1.74
+0.06
(+3.57%)
USD |
OTCM |
Jun 09, 16:00
Interpace Biosciences Enterprise Value : 46.63M for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 46.63M |
| June 08, 2026 | 44.97M |
| June 05, 2026 | 44.69M |
| June 04, 2026 | 48.02M |
| June 03, 2026 | 46.91M |
| June 02, 2026 | 47.19M |
| June 01, 2026 | 46.08M |
| May 29, 2026 | 45.52M |
| May 28, 2026 | 48.29M |
| May 27, 2026 | 48.29M |
| May 26, 2026 | 48.29M |
| May 22, 2026 | 48.85M |
| May 21, 2026 | 48.29M |
| May 20, 2026 | 48.29M |
| May 19, 2026 | 48.29M |
| May 18, 2026 | 46.91M |
| May 15, 2026 | 47.75M |
| May 14, 2026 | 48.29M |
| May 13, 2026 | 51.06M |
| May 12, 2026 | 53.83M |
| May 11, 2026 | 55.81M |
| May 08, 2026 | 52.45M |
| May 07, 2026 | 53.83M |
| May 06, 2026 | 56.89M |
| May 05, 2026 | 54.06M |
| Date | Value |
|---|---|
| May 04, 2026 | 53.83M |
| May 01, 2026 | 57.16M |
| April 30, 2026 | 53.28M |
| April 29, 2026 | 53.56M |
| April 28, 2026 | 52.01M |
| April 27, 2026 | 52.01M |
| April 24, 2026 | 53.14M |
| April 23, 2026 | 54.47M |
| April 22, 2026 | 53.77M |
| April 21, 2026 | 53.83M |
| April 20, 2026 | 55.11M |
| April 17, 2026 | 57.57M |
| April 16, 2026 | 59.38M |
| April 15, 2026 | 59.38M |
| April 14, 2026 | 59.38M |
| April 13, 2026 | 59.38M |
| April 10, 2026 | 62.15M |
| April 09, 2026 | 62.15M |
| April 08, 2026 | 53.35M |
| April 07, 2026 | 53.70M |
| April 06, 2026 | 53.00M |
| April 02, 2026 | 52.66M |
| April 01, 2026 | 49.68M |
| March 31, 2026 | 50.79M |
| March 30, 2026 | 6.029M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Medical Marijuana, Inc. | 2.962M |
| Acro Biomedical Co. Ltd. | 1.932M |
| Stella Diagnostics, Inc. | 20.55M |
| Wellgistics Health, Inc. | 37.53M |
| IDEXX Laboratories, Inc. | 46.78B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.831M |
| Revenue (Quarterly) | 9.032M |
| Total Expenses (Quarterly) | 8.201M |
| EPS Diluted (Quarterly) | 0.026 |
| Gross Profit Margin (Quarterly) | 65.37% |
| Profit Margin (Quarterly) | 9.20% |
| Earnings Yield | 42.07% |
| Operating Earnings Yield | 8.87% |
| Normalized Earnings Yield | 41.83 |